FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma

By afschroeder • July 20, 2025

Smyth EC, Kim KM, Rha SY, Wainberg ZA, Honeycutt H, Sommermann E, Ochiai A. FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma. Cancer Treat Rev. 2025 May 26;139:102971. doi: 10.1016/j.ctrv.2025.102971. Epub ahead of print. PMID: 40680491.

Tags: biomarkers, Fgfr2b, Fibroblast growth factor receptor, Fibroblast growth receptor 2b, gastric cancer, Hematology/Oncology, Publications, targeted therapy

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT)

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin[...]

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]